演題詳細

一般口演 / Oral Session

一般口演 25 (Oral Session 25) :CML:基礎 2

print

日程
2013年10月11日(金)
時間
14:25 - 15:25
会場
第7会場 / Room No.7 (ロイトン札幌 2F リージェント)
座長・司会
中前 博久 (Hirohisa Nakamae):1
1:大阪市立大学大学院医学研究科 血液腫瘍制御学
 
前へ戻る

Dasatinib specifically increases CD57+CD14- cells, associated with decreased M-BCR-ABL mRNA in CML

演題番号 : OS-1-125

熊谷 隆志 (Takashi Kumagai):1、松木 絵里 (Eri Matsuki):2、猪口 孝一 (Koichi Inokuchi):3、大橋 一輝 (Kazuteru Ohashi):4、品川 篤司 (Atsushi Shinagawa):5、竹内 仁 (Jin Takeuchi):6、吉田 近思 (Chikashi Yoshida):7、岡本 真一郎 (Shinichiro Okamoto):2、脇田 久 (Hisashi Wakita):8、香西 康司 (Yasuji Kouzai):9、白杉 由香里 (Yukari Shirasugi):10、藤沢 信 (Shin Fujisawa):11、岩瀬 理 (Osamu Iwase):12、矢野 真吾 (Shingo Yano):13、西脇 嘉一 (Kaichi Nishiwaki):14、大庭 幸治 (Koji Oba):15、坂本 純一 (Junichi Sakamoto):16、坂巻 壽 (Hisashi Sakamaki):4

1:Department of Hematology, Ohme Municipal General Hospital, Tokyo, Japan、2:Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan、3:Division of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan、4:Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan、5:Department of Internal Medicine, Hitachi General Hospital, Hitachi, Ibaraki, Japan、6:Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan、7:Department of Hematology, National Hospital Organization Mito Medical Center, Ibaraki, Japan、8:Division of Hematology and Oncology, Japanese Red Cross Society, Narita Red Cross Hospital, Narita, Japan、9:Department of Hematology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan、10:Division of Hematology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan、11:Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan、12:Division of Hematology, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan、13:Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan、14:Division of Oncology and Hematology, Department of Internal Medicine, Jikei University Kashiwa Hospital, Kashiwa, Japan、15:Translational Research and Clinical Trial Center, Hokkaido University Hospital, Hokkaido, Japan、16:Tokai Central Hospital, Kakamigahara, Japan

 

Dasatinib (DAS) has been widely used for CML uniquely causing lymphocytosis with LGL morphology associated with good response. In Japanese phase II study, we prospectively evaluated lymphocyte profiles of 50 imatinib-resistant or -intolerant CML patients treated with DAS by flow cytometry. We have shown relative lymphocyte counts >150% as well as subset of CD57+CD14-, CD8+T, or NK cells >200% at 1 month of treatment could predict improved response to DAS. (1) In further study, transcriptional levels of major BCR-ABL had significantly negative correlations with relative increases in lymphocyte count at 1 and 3 months (p=0.043 and 0.006). We also obtained following results in further study in patients with improved response. (2) DAS significantly stimulated proliferations of T and NK, but not B cells. The increased cell numbers with CD57+CD14-; cells and those of T+NK cells were similar until 6 months, suggesting specific stimulation of CD57+CD14-;, LGL phenotypic cells by DAS. (3) Both CD57+CD3+ (T-LGL) or CD57+CD56+ (NK-LGL) cells were significantly increased by approximately 6 folds at 6 months (p=0.008 and 0.028). (4) CD8+T cells were significantly increased by DAS without increase in other T cells, suggesting specific stimulation of T-LGL in T cell population. In summary, we confirmed the relative increase in lymphocyte by DAS as a marker of decreased major BCR-ABL transcripts and DAS specifically stimulated increase in LGL phenotypic cells consisting of T-LGLs and NK-LGLs associated with good response.

前へ戻る